Fresenius Medical Care Spon Adr-each Rep 0.5 Npv (FMS) Stock
Global dialysis services and products provider. Here's the price, business snapshot, and what's worth knowing about Fresenius Medical Care Spon Adr-each Rep 0.5 Npv in June 2026.
Fresenius Medical Care AG & Co. KGaA (ticker: FMS) is a global healthcare company specialising in dialysis services and products. It operates a network of renal care clinics and supplies machines, disposables and associated therapies. Investors should note the business combines recurring-revenue clinic treatments with product sales, which can provide steady cash flow but also ties performance to patient volumes, reimbursement rates and product adoption. Demographic trends such as ageing populations support long-term demand, while regulatory oversight, reimbursement pressures and operational complexity are meaningful risks. Financial specifics such as market capitalisation and recent results change frequently — check current market data before making decisions. This summary is for general educational purposes only and not personalised investment advice; values can rise and fall and past performance does not guarantee future returns. Consider your risk tolerance and investment horizon when assessing any position in FMS.
Stock Performance Snapshot
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FMS
Rare Kidney Disease Treatments | A Market Overview
The FDA's expanded approval of Travere's FILSPARI validates the growing market for rare nephrology treatments. This milestone creates positive momentum for biopharma companies developing innovative therapies for underserved kidney conditions.
Published: 14 April 2026
Explore BasketRenal Therapy Stocks (Biopharma & Research) In Focus
Vertex Pharmaceuticals recently achieved significant late-stage trial success for its experimental kidney disease drug, paving the way for accelerated regulatory approval. This breakthrough spotlights a broader investment opportunity in biopharmaceutical companies and medical researchers developing innovative treatments for chronic renal conditions.
Published: 10 March 2026
Explore BasketGerman Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: 15 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady service demand
Dialysis treatments create recurring revenue that can support predictability, though volumes and reimbursement rates can change.
Global footprint matters
A wide clinic network offers growth and diversification but also exposes the company to regulatory and currency risks across regions.
Product and tech focus
Innovation in machines and consumables can improve margins and outcomes, yet competition and R&D costs add uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
